PUBLISHED DATE : Apr 2020 | Pages : 269
Fill out your details & get your free sample
Premature Ejaculation Market Size, Share, & Trends Analysis Report Research Report by Drug Class (SSRIs, PDE5 Inhibitors, Anesthetic Agents, and Others), Route of Administration (ROA) (Oral PE Therapeutics and Topical PE therapeutics), and Geography (APAC, Europe, North America, Latin America, and Middle East & Africa), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020-2025
269 Pages
54 Tables
155 Charts
5 Regions
19 Countries
15 Companies
3 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (Revenue) | USD 2 BILLION (2025) |
| CAGR | 8% (2020-2025) |
| Base Year | 2019 |
| Forecast Year | 2020-2025 |
| Market Segments | Drug Class (SSRIs, PDE5 Inhibitors, Anesthetic Agents, and Others), Route of Administration (ROA) (Oral PE Therapeutics and Topical PE therapeutics) |
| Geographic Analysis | APAC, Europe, North America, Latin America, and Middle East & Africa |
| Countries Covered | US, Canada, Germany, France, UK, Italy, Spain, Japan, China, India, South Korea, Brazil, Mexico, Argentina, Turkey, Saudi Arabia, South Africa, and Iran |
The global premature ejaculation (PE) market size will reach USD 2 billion in 2025 is expected to grow at a steady CAGR during the forecast period. The market growth can be mainly attributed to the growing prevalence of premature ejaculation (PE) among men globally. PE is the most prevalent sexual dysfunction among men the world over. With the presence of a single approved oral drug, the PE therapeutics market is dominated by off-label drugs, generic versions of patent expired drugs, and OTC formulations, both regionally as well as globally. The increasing demand for several off-label and generic drugs is a primary factor driving the growth of the market. The treatment with off-label drugs belonging to SSRIs and topical formulations has revolutionized the treatment approach. Several vendors are offering off-label drugs that belong to different drug classes such as SSRIs and PDE5 inhibitors and OTC topical creams/sprays for treatment. Therefore, the demand for such drugs is likely to increase at a steady rate globally.
Another advance is the advent of metered-dose delivery systems. Several OTC anesthetic sprays are formulated to deliver the drug through a metered-dose administration. Metered-dose delivery systems deliver lidocaine and prilocaine in base form without organic solvents. Such drugs can be easily removed before vaginal penetration, thus circumventing the need for a condom that most patients find uncomfortable. Hence, such advanced formulations are likely to boost the future growth of the global PE therapeutics market.
This research report offers a detailed segmentation by
The SSRIs segment is likely to retain its market dominance during the forecast period. SSRIs are considered as effective drugs for the treatment of PE, and they majorly include paroxetine, sertraline, fluoxetine, citalopram, escitalopram, and dapoxetine. Several evidence-based studies have demonstrated the safety and efficacy of SSRIs in delaying ejaculation, which ensures their role as first-line agents for the treatment of lifelong and acquired PE. The growth of the segment is likely to be facilitated by an increase in the number of countries gaining approval for the use of Priligy. The increased recommendation of SSRIs by healthcare professionals is one of the key factors for the growth of the segment worldwide.
The increase in the share of the PDE5 inhibitors segment can be mainly attributed to the brand value of existing PDE5 inhibitor drugs, which facilitate high uptake among patients, especially for self-management. Anesthetic agents have proved effective and are generally tolerated for patients with PE. Several topical anesthetics are inexpensive and readily available from pharmacies, thereby allowing them an easy medication to buy. The segment is likely to witness a higher CAGR during the forecast period than other drug therapies. The expected launch of new licensed/unlicensed OTC products worldwide is the prime factor enhancing growth.
Oral therapeutics consists of tablets, capsules, solutions, and suspensions. Several oral agents, specifically SSRIs, tramadol, and dapoxetine, have proven effective and safe for the treatment of PE. Hence, several HCPs are recommending oral therapeutics as a primary treatment option to manage premature ejaculation. A daily dose of oral therapies has exhibited improved and enhanced efficacy over topical therapies. Therefore, the demand for oral therapeutics is increasing at a steady-state worldwide. Moreover, the growing pervasiveness of PE and the increasing uptake of generic off-label medications are the key factors enabling the growth of the oral ROA segment.
Topical medications refer to the drugs that are applied to the skin and include creams, gels, sprays, powders, emulsion, solutions, and ointments. These drugs are often used as “a needed option” for efficient management of PE and erectile dysfunction. Therefore, the segment accounts for a smaller share than oral therapeutics. Easy availability of several topical medicines at multiple sales channels acts as one of the key factors, which boosts the product uptake of topical therapies in the vast majority of patients.
North America is the major revenue contributor to the global premature ejaculation therapeutics market. The presence of a large disease population, coupled with better access to healthcare, especially OTC drugs, and increased focus on sexual wellness products is the primary factor for high shares. The strong presence of key vendors is also another reason for high product uptake in the region.
The presence of major vendors, better disease awareness, high healthcare spending on sexual wellbeing is the primary factor for high market share in this region. Germany, the UK, France, Italy, and Spain are the major revenue contributors. The increasing treatment-seeking population will mainly drive the market in Europe due to improved PE awareness and increased patient focus on healthy sexual well-being.
A low treatment-seeking population associated with social stigma in select regions, lack of awareness, and comparatively less access to healthcare services, especially in developing countries, are few factors that limit the growth of the market in this region. Japan, India, China, Australia, and South Korea are the major revenue contributors in the region.
The Latin American market is expected to grow at a higher rate than other regions during the forecast period. A high prevalence of PE, improvement in healthcare spending, an increase in awareness, an increase in uptake of drugs, especially generic off-label drugs and low-cost OTC drugs will fuel the growth of premature ejaculation therapeutics market in this region. The prevalence rate of PE in Latin America is estimated to be higher than in Europe. The average prevalence rate in this region is estimated at 28%. However, an increase in disease awareness, willingness to seek professional help for disease management, high prevalence of chronic psychological and other male sexual health disorders, especially ED, are contributing to the growth of the PE therapeutics market in this region.
Low access to healthcare facilities, inadequacy in a number of specialized health professionals, and lack of awareness about the disease and its treatment options are the key reasons for the low market size of premature ejaculation treatment despite high market potential. Therefore, the market is expected to witness slow growth than other regions in the coming years.
The global premature ejaculation therapeutics market is fairly fragmented and is characterized by the presence of both pharmaceutical companies and generic manufacturers offering off-label branded drugs and generics. Vendors are offering off-label drugs, generic versions, and OTC topical anesthetic agents. Companies offering topical anesthetic drug formulations are gaining widespread popularity than manufacturers offering oral PE therapeutics. Pfizer, Bayer, Eli Lilly and Company, and GlaxoSmithKline are also being used as off-label drugs. Therefore, these global players have a significant presence in the market as physicians, especially in select countries such as the US, Germany, and Japan and are prescribing popular brands such as Paxil, Zoloft, Viagra, Levitra, and Cialis as off-label drugs. However, due to their high cost, a broad majority of physicians worldwide are recommending low-cost generic versions of these popular prescription drugs. Therefore, the market has witnessed the entry of many generic manufacturers offering generic drugs of the patent expired drugs at a low price.
Segmentation by Drug Class
By ROA
By Geography
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
Fill out your details & get your free sample
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
Want to know more about the report or any specific requirement?
Click to Email +1-312-235-2040
